68 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
7 May 24
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
7:03am
and Development Expenses: Research and development (R&D) expenses for the three months ended March 31, 2024, were $49.6 million, compared to $48.6 million …
stock) as of March 31, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements into mid-2026.
Research
S-3ASR
ZNTL
Zentalis Pharmaceuticals Inc
29 Feb 24
Automatic shelf registration
5:14pm
to advance the clinical development of azenosertib, ZN-d5 and any other product candidates, fund new and ongoing research and development activities … the clinical development of azenosertib, ZN-d5 and any other product candidates, fund new and ongoing research and development activities, and for working
8-K
EX-99.1
7ky18 3okz5rimd780q
27 Feb 24
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
7:04am
8-K
EX-99.1
ayjzgd6ash2db3l1
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
8-K
EX-99.1
q7elxva9588 01sa99d
9 Aug 23
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
7:03am
424B5
ywszs58b6s
15 Jun 23
Prospectus supplement for primary offering
4:12pm
8-K
EX-99.1
0176wp
10 May 23
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
7:04am
PRE 14A
8x9hfd9kp3
18 Apr 23
Preliminary proxy
4:30pm
8-K
EX-99.1
0oe9g8354
9 Nov 22
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
7:04am
8-K
EX-99.1
ag6o3 cc0x4trix
9 Aug 22
Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update
12:00am